In Vivo Imaging of BCR-Abl Overexpressing Tumors With a Radiolabeled Imatinib Analog as an Imaging Surrogate for Imatinib

Journal of Nuclear Medicine - China
doi 10.2967/jnumed.110.085050
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Society of Nuclear Medicine

Related search

A Non-Atp-Competitive Inhibitor of BCR-ABL Overrides Imatinib Resistance

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2005English

Identification of Drug Combinations Containing Imatinib for Treatment of BCR-ABL+ Leukemias

PLoS ONE
Multidisciplinary
2014English

In Vitro and in Vivo Activity of SKI-606, a Novel SRC-Abl Inhibitor, Against Imatinib-Resistant BCR-Abl+ Neoplastic Cells

Cancer Research
Cancer ResearchOncology
2006English

Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia

Cancer Research
Cancer ResearchOncology
2004English

Coexistence of AML1/RUNX1 and BCR-ABL Point Mutations in an Imatinib-Resistant Form of CML

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2005English

An Amino-Acid Switch in the BCR-ABL Kinase Domain Modifies Sensitivity to Imatinib Mesylate

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2005English

NPB001-05 Inhibits BCR-Abl Kinase Leading to Apoptosis of Imatinib-Resistant Cells

Frontiers in Bioscience - Elite
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2011English

ON012380: A Non-Atp Competitive Inhibitor of BCR-ABL for the Therapy of Imatinib-Resistant CMLs

2009English

Nilotinib Significantly Induces Apoptosis in Imatinib Resistant K562 Cells With Wild-Type BCR–ABL, as Effectively as in Parental Sensitive Counterparts

Hematology
Hematology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy